Press

Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

Dec 9 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in an industry panel and host one-on-one investor meetings at the virtual Canaccord Genuity…

The Addition of Three Mental Health Clinics to Irwin Naturals’ Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental Health Clinics

Dec 9 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center. The Company entered into an acquisition agreement dated October 30, 2022 with Clare Clinic, Inc., d/b/a Florida Mind Health Center, which serves clients out of three healthcare clinics in located in…

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Dec 8 • 3 min read

Diamond Therapeutics Inc., a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, announces the successful completion of its Phase I clinical study of low-dose psilocybin. Regulated by Health Canada, Diamond’s study is the first randomized, double-blind, and placebo-controlled single ascending dose study to investigate low doses of…

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Dec 8 • 3 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of three additional U.S. Provisional Patent Applications covering its latest discoveries. This bring the total number of provisional applications filed by PsyBio…

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

Dec 8 • 3 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy (PAT) the ability to…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441